Incidence of constipation associated with long-acting opioid therapy: A comparative study

被引:50
|
作者
Staats, PS
Markwitz, J
Schein, J
机构
[1] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Hlth Data Analyt, Princeton, NJ USA
[4] Janssen Pharmaceut Prod LP, Titusville, NJ USA
关键词
constipation; fentanyl transdermal system; morphine; controlled-release; opioid analgesics; oxycodone controlled-release;
D O I
10.1097/01.SMJ.0000109215.54052.D8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy. Methods: A retrospective cohort design study was conducted determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared. Results: A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group. Conclusion: In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 50 条
  • [31] RELATIVE EFFICACY AND POTENCY OF NALMEFENE, A LONG-ACTING OPIOID ANTAGONIST
    WATSON, NA
    MUNDAY, IT
    JONES, RM
    BRITISH JOURNAL OF ANAESTHESIA, 1993, 70 (04) : P479 - P479
  • [33] Long-Acting Growth Hormone for Replacement Therapy
    Johannsson, Gudmundur
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06): : 1668 - 1670
  • [34] Long-acting beta agonists in asthma therapy
    Richard W. Rissmiller
    Michael J. Larj
    Stephen P. Peters
    Current Allergy and Asthma Reports, 2004, 4 : 91 - 92
  • [35] Long-acting cocaine hydrolase for addiction therapy
    Chen, Xiabin
    Xue, Liu
    Hou, Shurong
    Jin, Zhenyu
    Zhang, Ting
    Zheng, Fang
    Zhan, Chang-Guo
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (02) : 422 - 427
  • [36] LONG-ACTING INJECTABLE THERAPY FOR FERTILITY CONTROL
    VIRKAR, KD
    KORA, SJ
    DIKSHIT, SS
    LODAYA, MJ
    JOURNAL OF REPRODUCTION AND FERTILITY, 1971, 27 (02): : 305 - &
  • [37] ROLE OF LONG-ACTING CEPHALOSPORINS IN AMBULATORY THERAPY
    PRICHARD, JG
    CLINICAL THERAPEUTICS, 1988, 10 (06) : 688 - 693
  • [38] Development of long-acting bisphosphonates for annual therapy
    Gasser, J. A.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S173 - S173
  • [39] Long-acting beta Agonists in asthma therapy
    Rissmiller, RW
    Larj, MJ
    Peters, SP
    CURRENT ALLERGY AND ASTHMA REPORTS, 2004, 4 (02) : 91 - 92
  • [40] Pump therapy or long-acting insulin analogue?
    Holt, RIG
    DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 113 - 114